Subscribe To
Us judge blasted for secrecy in google antitrust case after presiding over jan. 6 trials
Judge Amit P. Mehta is solely responsible for deciding if Google has broken the law in its quest to maintain dominance....
September 29, 2023, 6:16 pm
Economic institutions lowered their forecasts for german gdp. oil updates highs again
By JustMarkets At yesterday’s stock market close, the Dow Jones Index (US30) decreased by 0.20%, while the S&P 500 Index (US500) added 0.02%. The NA...
September 28, 2023, 12:10 pm
Nxu launches revenue-generating ev charging field trials in celebration of national drive electric week
Nxu One Megawatt+ Charging System is Open to the Public with $1 Charging Promotion MESA, Ariz., Sept. 28, 2023 (GLOBE NEWSWIRE) — Nxu Inc., (NASDAQ:...
September 28, 2023, 10:30 am
Aclaris therapeutics: the many lives of this biopharmaceutical developer
Aclaris Therapeutics is a developer of kinome-based medicines for immune-inflammatory and oncology indications. The company's platform, KINect, helps ...
September 28, 2023, 7:18 am
Moonlake immunotherapeutics is now thoroughly de-risked
MoonLake Immunotherapeutics has seen success in the last 5 months after positive data from a phase 2 trial of sonelokimab in hidradenitis suppurativa....
September 27, 2023, 8:00 pm
Standex to present at william blair's what's next for industrials conference
SALEM, N.H. , Sept. 27, 2023 /PRNewswire/ -- Standex International Corporation (NYSE:SXI) announced today that David Dunbar, President & CEO, and Ade...
September 27, 2023, 5:26 pm
Intraoperative radiation therapy systems market poised for a 7.7% cagr surge, reaching us$ 124.7 million by 2033 | future market insights inc.
Intraoperative Radiation Therapy Systems: Advancing Cancer Care. IORT’s precision, clinical trials an...
September 27, 2023, 2:30 pm
Is spdr s&p homebuilders etf (xhb) a strong etf right now?
Designed to provide broad exposure to the Industrials ETFs category of the market, the SPDR S&P Homebui...
September 27, 2023, 7:31 am
Costco share fall following results, while cardiff oncology and millerknoll shares soar, and more moving stocks
Cardiff Oncology Inc. CRDF, +0.62% shares surged 32% on favorable data from two cancer drug trials — ...
September 27, 2023, 5:56 am
Immunovant: immune boost, from clinical trials to an aggressive bullish stock
Although Immunovant's stock has rallied around 100% since January, recent data on its therapeutic candidate, IMVT-1402, has further bolstered confiden...
September 27, 2023, 5:30 am
: corrected: dow closes below 200-day moving average, as long-term treasury yields climb
This article has been updated to reflect the correct date when the Dow Industrials last fell below its ...
September 26, 2023, 8:58 pm
Scynexis: from fungal to bungle, the brexafemme recall and a slippery slope (rating downgrade)
We downgrade Scynexis to a sell rating following the voluntary recall of antifungal pill, Brexafemme. Historical precedence suggests that manufacturin...
September 26, 2023, 7:54 pm
Biogen inc. (biib) management presents at decentralized clinical trials in focus conference (transcript)
Biogen Inc. (NASDAQ:BIIB ) Decentralized Clinical trials in Focus Conference September 26, 2023 10:00 A...
September 26, 2023, 5:17 pm
Summit therapeutics: not for retail investors
Summit Therapeutics Inc., backed by biotech billionaire Bob Duggan, has transitioned from developing antibiotics to becoming an oncology therapeutics ...
September 26, 2023, 3:00 pm
4d molecular therapeutics: some failures, a few key successes
4D Molecular Therapeutics, Inc. has faced setbacks, with the FDA placing a clinical hold on its Fabry Disease program due to serious kidney conditions...
September 25, 2023, 12:19 pm
Littelfuse: e-mobility and m&a could bring substantial market attention
Littelfuse is a global industrial technology company that may benefit from investment trends in sustainability, connectivity, and security. The compan...
September 25, 2023, 7:52 am
Should you invest in the spdr s&p homebuilders etf (xhb)?
Looking for broad exposure to the Industrials - Engineering and Construction segment of the equity mark...
September 25, 2023, 7:31 am
Aldeyra:upcoming pdufa, strong nda, long pipeline, decent cash
Aldeyra is a late-stage company developing therapies for immune-mediated diseases, with a focus on dry eye disease and allergic conjunctivitis. Their ...
September 22, 2023, 7:44 pm
Merck and eisai say two lung-cancer trials failed to meet their main goals
Merck and Japanese partner Eisai said Friday that two late-stage trials of a treatment for a certain ty...
September 22, 2023, 7:31 am
Prothena: switching from 'hold' to 'buy' on lead alzheimer's drug promise
Prothena Corporation is a protein dysregulation specialist with a focus on developing drugs for Alzheimer's disease. The company's lead candidate, PRX...
September 21, 2023, 1:39 pm